-
公开(公告)号：US20190202873A1
公开(公告)日：2019-07-04
申请号：US16359267
申请日：2019-03-20
申请人： Wyeth LLC
发明人： Kathrin Ute Jansen , Annaliesa Sybil Anderson , Robert G.K. Donald , Maninder K. Sidhu , Narender Kumar Kalyan , Justin Keith Moran , Mark Edward Ruppen , Michael James Flint
摘要： In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
-
公开(公告)号：US20130330371A1
公开(公告)日：2013-12-12
申请号：US13970048
申请日：2013-08-19
申请人： WYETH LLC
发明人： Annaliesa Sybil Anderson , Maninder K. Sidhu , Robert G. K. Donald , Kathrin Ute Jansen , Narender Kumar Kalyan , Justin Keith Moran , Mark E. Ruppen , Michael James Flint
CPC分类号： C07K14/33 , A61K39/08 , C07K16/1282 , C07K2317/33 , C07K2317/76 , C07K2317/92 , C12N9/1051 , C12N9/99 , C12N15/74
摘要： In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
-
公开(公告)号：US11077180B2
公开(公告)日：2021-08-03
申请号：US16598661
申请日：2019-10-10
申请人： Wyeth LLC
发明人： Annaliesa Sybil Anderson , Kathrin Ute Jansen , Mark Edward Ruppen , Justin Keith Moran , Susan Kay Hoiseth
IPC分类号： A61K39/095 , C07K14/22 , C07K16/12 , A61K39/00
摘要： The present invention relates to compositions including an isolated non-pyruvylated non-lipidated ORF2086 polypeptide, and methods thereof. In an exemplary embodiment, the compositions described herein are immunogenic. The present invention further relates to compositions that elicit a bactericidal immune response in a mammal against an ORF2086 subfamily B polypeptide from serogroup B Neisseria meningitidis, and methods related thereto.
-
公开(公告)号：US20170326222A1
公开(公告)日：2017-11-16
申请号：US15587574
申请日：2017-05-05
申请人： Wyeth LLC
发明人： Annaliesa Sybil Anderson , Kathrin Ute Jansen , Mark Edward Ruppen , Justin Keith Moran , Susan Kay Hoiseth
IPC分类号： A61K39/095 , C07K14/22 , A61K39/00
摘要： The present invention relates to compositions including an isolated non-pyruvylated non-lipidated ORF2086 polypeptide, and methods thereof. In an exemplary embodiment, the compositions described herein are immunogenic. The present invention further relates to compositions that elicit a bactericidal immune response in a mammal against an ORF2086 subfamily B polypeptide from serogroup B Neisseria meningitidis, and methods related thereto.
-
公开(公告)号：USRE46376E1
公开(公告)日：2017-04-25
申请号：US14883000
申请日：2015-10-14
申请人： WYETH LLC
CPC分类号： C07K14/33 , A61K39/08 , C07K16/1282 , C07K2317/33 , C07K2317/76 , C07K2317/92 , C12N9/1051 , C12N9/99 , C12N15/74
摘要： In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
-
公开(公告)号：US20150125927A1
公开(公告)日：2015-05-07
申请号：US14529147
申请日：2014-10-31
申请人： WYETH LLC
发明人： Mark E. Ruppen , Justin Keith Moran , Kathrin Ute Jansen , Annaliesa Sybil Anderson , Robert G. K. Donald , Narender K. Kalyan , Maninder K. Sidhu , Michael James Flint
IPC分类号： C12N9/10
CPC分类号： C07K14/33 , A61K39/08 , C07K16/1282 , C07K2317/33 , C07K2317/76 , C07K2317/92 , C12N9/1051 , C12N9/99 , C12N15/74
摘要： In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
-
公开(公告)号：US08557548B2
公开(公告)日：2013-10-15
申请号：US13848909
申请日：2013-03-22
申请人： Wyeth LLC
CPC分类号： C07K14/33 , A61K39/08 , C07K16/1282 , C07K2317/33 , C07K2317/76 , C07K2317/92 , C12N9/1051 , C12N9/99 , C12N15/74
摘要： In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
-
公开(公告)号：US20200095290A1
公开(公告)日：2020-03-26
申请号：US16704777
申请日：2019-12-05
申请人： Wyeth LLC
发明人： Kathrin Ute Jansen , Annaliesa Sybil Anderson , Robert G.K. Donald , Maninder K. Sidhu , Narender Kumar Kalyan , Justin Keith Moran , Mark Edward Ruppen , Michael James Flint
摘要： In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
-
公开(公告)号：US10512681B2
公开(公告)日：2019-12-24
申请号：US15587574
申请日：2017-05-05
申请人： Wyeth LLC
发明人： Annaliesa Sybil Anderson , Kathrin Ute Jansen , Mark Edward Ruppen , Justin Keith Moran , Susan Kay Hoiseth
IPC分类号： A61K39/095 , C07K14/22 , C07K16/12 , A61K39/00
摘要： The present invention relates to compositions including an isolated non-pyruvylated non-lipidated ORF2086 polypeptide, and methods thereof. In an exemplary embodiment, the compositions described herein are immunogenic. The present invention further relates to compositions that elicit a bactericidal immune response in a mammal against an ORF2086 subfamily B polypeptide from serogroup B Neisseria meningitidis, and methods related thereto.
-
公开(公告)号：US09745354B2
公开(公告)日：2017-08-29
申请号：US14529147
申请日：2014-10-31
申请人： WYETH LLC
发明人： Mark E. Ruppen , Justin Keith Moran , Kathrin Ute Jansen , Annaliesa Sybil Anderson , Robert G. K. Donald , Narender K. Kalyan , Maninder K. Sidhu , Michael James Flint
CPC分类号： C07K14/33 , A61K39/08 , C07K16/1282 , C07K2317/33 , C07K2317/76 , C07K2317/92 , C12N9/1051 , C12N9/99 , C12N15/74
摘要： In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
-
-
-
-
-
-
-
-
-
搜索结果
25 条记录 (耗时 0.039 秒)
